Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Nov 5;6(1):FSO429.
doi: 10.2144/fsoa-2019-0089.

Transvaginal laparoscopic salpingo-oophorectomy: an oncological risk-reducing procedure

Kostas Lathouras  1 , Srdjan Saso  1 , Benjamin P Jones  1 , Sarah Bowden  1 , Maria Kyrgiou  1 , Anna Stienen-Durand  2 , Gareth Beynon  2
Affiliations

Transvaginal laparoscopic salpingo-oophorectomy: an oncological risk-reducing procedure

Kostas Lathouras et al. Future Sci OA. .

Abstract

Aim: Since the first natural orifice transluminal endoscopic surgery procedure, renewed interest has arisen in further developing and advancing minimal access surgery. We introduce a natural orifice endoscopic approach for a bilateral salpingo-oophorectomy.

Patients & methods: Using the vagina as a natural orifice, we performed a transvaginal laparoscopic salpingo-oophorectomy to remove bilateral adnexa in patients with a strong family history of ovarian and/or breast cancer and those positive for BRCA1/2 mutation.

Results: Total 36 women underwent transvaginal laparoscopic salpingo-oophorectomy. Conversion to routine laparoscopy was required in eight patients to complete the operation. No peri-operative complications were noted.

Conclusion: We describe a novel approach in gynecological surgery. Our technique proved to be safe and efficient with the advantage of avoiding any abdominal scars.

Keywords: BRCA1/2; natural orifice transluminal endoscopic surgery; salpingo-oophorectomy; transvaginal endoscopy.

PubMed Disclaimer

Conflict of interest statement

Financial & competing interests disclosure The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties. No writing assistance was utilized in the production of this manuscript.

Figures

Figure 1.
Figure 1.. Pictorial representation of port sites in vaginal orifice.
Figure 2.
Figure 2.. Right utero-ovarian ligament.
Figure 3.
Figure 3.. Right infundibulo-pelvic ligament.
Figure 4.
Figure 4.. Left utero-ovarian ligament.
Figure 5.
Figure 5.. Left infundibulo-pelvic ligament.
See this image and copyright information in PMC

References

    1. Early Breast Cancer Trialists Collaborative Group (EBCTG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of randomized trials. Lancet 365(9472), 1687–1717 (2005). - PubMed
    1. Pritchard KI. Ovarian suppression/ablation in premenopausal ER-positive breast cancer patients. Issues and recommendations. Oncology 23(1), 27–33 (2009). - PubMed
    1. Antoniou A, Pharoah PD, Narod S. et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am. J. Hum. Genet. 72(5), 1117–1130 (2003). - PMC - PubMed
    1. Metcalfe KA, Lynch HT, Ghadirian P. et al. The risk of ovarian cancer after breast cancer in BRCA1 and BRCA2 carriers. Gynecol. Oncol. 96(1), 222–226 (2005). - PubMed
    1. Rebbeck TR, Lynch HT, Neuhausen SL. et al. Prophylactic oophrectomy in carriers of BRCA1 or BRCA2 mutations. N. Engl. J. Med. 346(21), 1616–1622 (2002). - PubMed

LinkOut - more resources